Exploring the association between different anti-PD-1 agents, such as pembrolizumab and sintilimab, and survival and response rates in these patients could offer valuable insights into whether different PD-1 inhibitors independently impact tumor outcomes. The gene discussed is PDCD1; the disease is neoplasm.